Moderna shares environmental, social and governance highlights at first esg day

Moderna continues development of at least 15 vaccine programs targeting emerging or neglected infectious diseases by 2025 as part of global health program moderna is committed to clinical trial diversity to ensure health equity moderna working to achieve net-zero carbon emissions globally by 2030 in scopes 1 and 2 and is committed to defining science-based carbon reduction targets in scope 3 as of september 2022, 50% of moderna employees are women, including 41% of leaders at the vice president level or above virtual esg day to be held today at 9:00 a.m. et cambridge, ma / accesswire / november 10, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today highlighted progress on its environmental, social and governance (esg) strategy presented at the company's first esg day.
MRNA Ratings Summary
MRNA Quant Ranking